The 2022 Tandem Meetings | Outcomes of patients with BPDCN after alloHSCT

Hemant Murthy, MD, Mayo Clinic Florida, Jacksonville, FL, discusses the results of a study evaluating the outcomes of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) who have received an allogeneic transplant. Overall, the study reported that patients had a 5-year overall survival (OS) of 51%, and the non-relapse mortality (NRM) was 32%. In addition, patients aged 60 and over had a worse OS as well as an increased NRM. Patients in first complete remission (CR1) did better than patients in CR2 or later, which may be due to different induction strategies. There are now several immunotherapeutic induction strategies under investigation. This study demonstrates the efficacy of allogeneic transplantation in BPDCN and highlights the importance of getting patients in remission from diagnosis. In addition, Dr Murthy underlines that further work is necessary to optimize reduced-intensity transplantation and post-transplant strategies for elderly patients who are unable to undergo myeloablative conditioning. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.